While our investigation has identified fludarabine phosphate as a potential FDA-approved drug that can preferentially inhibit N-MYC overexpressing cells in vitro, we next examined if its application in xenograft models will reduce tumor growth. The gene discussed is MYCN; the disease is neoplasm.